New drug combo shows promise for rare salivary gland cancer
NCT ID NCT04895735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs—pemetrexed (chemotherapy) and pembrolizumab (immunotherapy)—in people with salivary gland cancer that has returned or spread. The goal is to see if this combo can shrink tumors or slow the disease. About 45 adults with advanced salivary gland cancer are taking part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Can a targeted drug shrink rare salivary gland tumors?
- Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
- New drug cocktail targets genetic weakness in rare cancer
- Drug duo takes on rare head and neck tumors
- Rare sinus cancer study aims to clarify treatment outcomes